NPC1 as a Modulator of Disease Severity and Viral Entry of SARSCoV- 2.
Curr Mol Med
; 21(1): 2-4, 2021.
Article
in English
| MEDLINE | ID: covidwho-1154163
ABSTRACT
The COVID-19 plague is hitting mankind. Several viruses, including SARS-CoV-1, MERS-CoV, EBOV, and SARS-CoV-2, use the endocytic machinery to enter the cell. Genomic variants in NPC1, which encodes for the endo-lysosomal Niemann-Pick type C1 protein, restricts the host-range of viruses in bats and susceptibility to infections in humans. Lack of NPC1 and its pharmacological suppression inhibits many viral infections including SARS-CoV-1 and Type I Feline Coronavirus Infection. Antiviral effects of NPC1-inhibiting drugs for COVID-19 treatment should be explored.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Intracellular Signaling Peptides and Proteins
/
SARS-CoV-2
/
COVID-19
Type of study:
Prognostic study
Topics:
Variants
Limits:
Humans
Language:
English
Journal:
Curr Mol Med
Journal subject:
Molecular Biology
Year:
2021
Document Type:
Article
Affiliation country:
1566524020666200713175426
Similar
MEDLINE
...
LILACS
LIS